Corbus Pharmaceuticals Holding (CRBP) - Total Assets
Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) holds total assets worth $109.51 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CRBP total equity for net asset value and shareholders' equity analysis.
Corbus Pharmaceuticals Holding - Total Assets Trend (2012–2024)
This chart illustrates how Corbus Pharmaceuticals Holding's total assets have evolved over time, based on quarterly financial data.
Corbus Pharmaceuticals Holding - Asset Composition Analysis
Current Asset Composition (December 2024)
Corbus Pharmaceuticals Holding's total assets of $109.51 Million consist of 98.1% current assets and 1.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Corbus Pharmaceuticals Holding's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CRBP market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Corbus Pharmaceuticals Holding's current assets represent 98.1% of total assets in 2024, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2024, down from 99.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Corbus Pharmaceuticals Holding Competitors by Total Assets
Key competitors of Corbus Pharmaceuticals Holding based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Corbus Pharmaceuticals Holding - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.31 | 13.84 | 2.89 |
| Quick Ratio | 6.31 | 13.84 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $90.51 Million | $149.26 Million | $60.18 Million |
Corbus Pharmaceuticals Holding - Advanced Valuation Insights
This section examines the relationship between Corbus Pharmaceuticals Holding's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | 451.4% |
| Total Assets | $155.88 Million |
| Market Capitalization | $133.75 Million USD |
Valuation Analysis
Near Book Valuation: The market values Corbus Pharmaceuticals Holding's assets close to their book value (0.86x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Corbus Pharmaceuticals Holding's assets grew by 451.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Corbus Pharmaceuticals Holding (2012–2024)
The table below shows the annual total assets of Corbus Pharmaceuticals Holding from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $155.88 Million | +451.35% |
| 2023-12-31 | $28.27 Million | -57.37% |
| 2022-12-31 | $66.31 Million | -38.45% |
| 2021-12-31 | $107.73 Million | +5.31% |
| 2020-12-31 | $102.29 Million | +108.16% |
| 2019-12-31 | $49.14 Million | +4.58% |
| 2018-12-31 | $46.99 Million | -29.84% |
| 2017-12-31 | $66.98 Million | +274.43% |
| 2016-12-31 | $17.89 Million | +38.93% |
| 2015-12-31 | $12.88 Million | +95.06% |
| 2014-12-31 | $6.60 Million | +2060.50% |
| 2013-12-31 | $305.52K | +55960.77% |
| 2012-12-31 | $544.98 | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation o… Read more